| | Application No. | Applicant(s) |
|--|--|------------------------------|
| Notice of Allowability | 10/506 920 | MIESNED ET AL |
| | 10/506,820 Examiner | WIESNER ET AL. Art Unit |
| | 7' N | 1005 |
| | Zinna Northington Davis | 1625 |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. | | |
| 1. This communication is responsive to the Amendment filed October 14, 2005. | | |
| 2. The allowed claim(s) is/are 20-35 (now renumbered as 1-16, respectively). | | |
| 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | |
| a) ⊠ All b) ☐ Some* c) ☐ None of the: | | |
| Certified copies of the priority documents have been received. | | |
| 2. Certified copies of the priority documents have been received in Application No | | |
| 3. Copies of the certified copies of the priority documents have been received in this national stage application from the | | |
| International Bureau (PCT Rule 17.2(a)). | | |
| * Certified copies not received: | | |
| Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. | | |
| 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. | | |
| 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. | | |
| (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached | | |
| 1) hereto or 2) to Paper No./Mail Date | | |
| (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date | | |
| Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). | | |
| DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. | | |
| | | |
| Attachment(s) | _ | |
| 1. Notice of References Cited (PTO-892) | | atent Application (PTO-152) |
| 2. Notice of Draftperson's Patent Drawing Review (PTO-948) | Interview Summary Paper No./Mail Dat | |
| 3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date | 08), 7. ⊠ Examiner's Amendr | ment/Comment |
| Examiner's Comment Regarding Requirement for Deposit of Biological Material | 8. X Examiner's Stateme | ent of Reasons for Allowance |
| | 9. | |
| | | |
| | | |
| | | |

Application/Control Number: 10/506,820

Art Unit: 1625

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. John Sopp on January 19, 2006.

2. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I: Claims 20-35, drawn to a chemical compound, a pharmaceutical composition, method of preparing, and method of treating various diseases using a compound of formula (I).

Group II: Claim 36, drawn to a method of treating a disease maintained or propagated by angiogenesis using a chemical compound of formula (I).

Inventions I-II are related as only process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP 806.05(h)). In the instant case, the claims are drafted as various method of using. See claims 35 and 36.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/506,820 Page 3

Art Unit: 1625

4. During a telephone conversation with Mr. John Sopp on January 19, 2006 a provisional election was made *without* traverse to prosecute the invention of Group I, claims 20-35. Claim 36 is withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

- 5. The application has been amended as follows:
 - A. Claim 36 has been canceled.
- B. At claims 21-32 and 35, the phrase "of formula I of claim 1" has been amended in favor of the phrase --of formula I of claim 20--.
 - C. At claim 30, a period is added at the end of the claim.
- D. At claim 35, 2nd line, the term "infections" has been amended in favor of the term --infection--.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

- 6. Applicants preserve the right to file divisional applications drawn to the non-elected subject matter of claim 36.
- 7. At claim 21-35, the amendment is made to correct the dependency.
- 8. At claim 35, the term "infections" was amended to a singular form.
- 9. Based upon the Amendment filed October 14, 2005, the rejections under 35 U.S.C. §112, 2nd paragraph and 35 U.S.C. §101 are withdrawn.
- 10. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

Art Unit: 1625

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna N. Davis whose telephone number is 571-272-0682.
- 12. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Zinna Northington Davis
Primary Examiner
Group 1600-AU 1625

Znd 01.23.2006